The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | ANDROMEDA: daratumumab & CyBorD for newly diagnosed AL amyloidosis
Here, Ashutosh Wechalekar, MBBS, FRCP, FRCPath, University College London Hospitals NHS Trust, London, UK, highlights promising treatment regimens for AL amyloidosis, including an update from the ANDROMEDA study (NCT03201965) looking at daratumumab combined with cyclophosphamide, bortezomib and dexamethasone (CyBorD).
Dr Wechalekar also discusses ixazomib plus lenalidomide and dexamethasone (IRd).
This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc) as part of the European Hematology Association (EHA) 2020 Virtual Meeting.
